Martha Q Lacy
#125,816
Most Influential Person Now
Researcher
Martha Q Lacy's AcademicInfluence.com Rankings
Martha Q Lacyengineering Degrees
Engineering
#4129
World Rank
#5296
Historical Rank
Biomedical Engineering
#242
World Rank
#249
Historical Rank
Download Badge
Engineering
Martha Q Lacy's Degrees
- Masters Biomedical Engineering Stanford University
Why Is Martha Q Lacy Influential?
(Suggest an Edit or Addition)Martha Q Lacy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival in multiple myeloma and the impact of novel therapies. (2008) (2142)
- Review of 1027 patients with newly diagnosed multiple myeloma. (2003) (2065)
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013) (1086)
- Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. (2004) (748)
- Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. (2012) (740)
- POEMS syndrome: definitions and long-term outcome. (2003) (695)
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. (2013) (684)
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. (2005) (649)
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009) (609)
- Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. (2002) (535)
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
- Prognostic value of bone marrow angiogenesis in multiple myeloma. (2000) (378)
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. (2005) (349)
- Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. (2013) (344)
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. (2014) (339)
- Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma (2007) (328)
- Clinical course of patients with relapsed multiple myeloma. (2004) (321)
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. (2009) (309)
- Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. (2004) (303)
- Genetic aberrations and survival in plasma cell leukemia (2008) (295)
- Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. (2002) (291)
- The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. (2003) (286)
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. (2001) (266)
- The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. (2007) (261)
- Remission of disseminated cancer after systemic oncolytic virotherapy. (2014) (249)
- Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. (2009) (241)
- Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. (2017) (236)
- Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. (2006) (235)
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. (2006) (230)
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. (2010) (229)
- Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma (2003) (227)
- Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. (2007) (226)
- Thalidomide as initial therapy for early-stage myeloma (2003) (224)
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. (2012) (221)
- Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. (2004) (215)
- Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. (2010) (212)
- Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. (2005) (211)
- Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. (1998) (205)
- Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma (2006) (200)
- A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy (2007) (199)
- Late‐onset noninfectious pulmonary complications after allogeneic bone marrow transplantation (1998) (193)
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (2010) (193)
- Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. (2004) (192)
- Thalidomide in the treatment of relapsed multiple myeloma. (2000) (187)
- Long-term survival (10 years or more) in 30 patients with primary amyloidosis. (1999) (187)
- Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. (2007) (186)
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. (2014) (185)
- Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. (2008) (185)
- Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. (2006) (181)
- Thalidomide for previously untreated indolent or smoldering multiple myeloma (2001) (180)
- Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. (2013) (171)
- Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma (2011) (170)
- The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. (2011) (167)
- Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. (2011) (164)
- Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil (2000) (157)
- Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. (2012) (157)
- Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. (2008) (156)
- Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. (2007) (155)
- Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. (2019) (154)
- Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis (2013) (151)
- Stem cell transplantation for the management of primary systemic amyloidosis. (2002) (150)
- Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. (2001) (148)
- The Well-Being and Personal Wellness Promotion Strategies of Medical Oncologists in the North Central Cancer Treatment Group (2005) (147)
- Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. (2008) (146)
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria (2018) (145)
- Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. (2013) (143)
- Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. (2009) (141)
- Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis (2003) (139)
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. (2012) (138)
- Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. (2003) (133)
- A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. (2013) (133)
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. (2010) (133)
- Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations (2006) (128)
- Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia (2006) (126)
- Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response (2007) (126)
- Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. (2012) (125)
- Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. (2004) (123)
- Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugs (2010) (123)
- Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. (2008) (121)
- IAP antagonists induce anti-tumor immunity in multiple myeloma (2016) (120)
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia (2001) (120)
- Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. (2008) (119)
- Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. (1996) (119)
- Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis (2008) (118)
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. (2012) (117)
- Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. (2003) (116)
- Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. (2010) (116)
- Amyloidosis: recognition, confirmation, prognosis, and therapy. (1999) (112)
- Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma (2009) (110)
- Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation (2001) (109)
- Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate (2004) (108)
- Therapy for Relapsed Multiple Myeloma: GUIDELINES FROM THE MAYO STRATIFICATION FOR MYELOMA AND RISK‐ADAPTED THERAPY (2017) (107)
- Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. (2014) (107)
- A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. (2005) (107)
- Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myeloma (2012) (106)
- Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. (2009) (106)
- Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express the Sodium Iodide Symporter in Patients with Recurrent or Refractory Multiple Myeloma (2017) (105)
- Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma (2014) (104)
- Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. (2005) (104)
- The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma (2004) (103)
- Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome (2008) (103)
- Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis (2011) (102)
- Prognostic value of angiogenesis in solitary bone plasmacytoma. (2003) (101)
- Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. (2005) (101)
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 (2017) (101)
- Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. (1999) (101)
- Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. (2010) (101)
- Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL) (2000) (101)
- Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. (2015) (100)
- 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis (2007) (99)
- Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma (2004) (95)
- Pomalidomide (CC4047) Plus Low Dose Dexamethasone (Pom/dex) Is Active and Well Tolerated in Lenalidomide Refractory Multiple Myeloma (MM). (2009) (95)
- Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report (2010) (94)
- The clinical significance of cereblon expression in multiple myeloma. (2014) (94)
- Immunoglobulin light chain amyloidosis and the kidney. (2002) (94)
- Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. (2008) (93)
- Clinical implication of centrosome amplification in plasma cell neoplasm. (2006) (92)
- 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. (2006) (92)
- Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. (2006) (90)
- Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. (2006) (90)
- Long-term outcome of autologous stem cell transplantation in light chain deposition disease. (2008) (90)
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma (2014) (89)
- Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. (2011) (89)
- Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival (2009) (88)
- Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category (2017) (88)
- Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis (2009) (87)
- High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy (2004) (87)
- Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. (2015) (86)
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma (2013) (85)
- High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. (2012) (84)
- Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. (2018) (83)
- Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report (2000) (81)
- Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis (2008) (81)
- Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement (2005) (80)
- Changes in serum‐free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis (2011) (80)
- Impact of early relapse after auto-SCT for multiple myeloma (2008) (79)
- Thromboembolic events with lenalidomide‐based therapy for multiple myeloma (2008) (79)
- Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. (2007) (77)
- Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study (2008) (77)
- Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy (2015) (76)
- Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. (1999) (75)
- Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement (2018) (75)
- Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. (1999) (75)
- Smoldering multiple myeloma requiring treatment: time for a new definition? (2013) (74)
- Outcomes of patients with renal monoclonal immunoglobulin deposition disease (2016) (74)
- Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis (2001) (74)
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. (2011) (74)
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. (2013) (73)
- Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation (2001) (73)
- Primary systemic amyloidosis: a cause of malabsorption syndrome. (2001) (72)
- Outcomes of patients with POEMS syndrome treated initially with radiation. (2012) (71)
- Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. (2005) (70)
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. (2014) (70)
- Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy (2004) (70)
- Trends and outcomes of modern staging of solitary plasmacytoma of bone (2012) (70)
- Quantification of clonal circulating plasma cells in relapsed multiple myeloma (2014) (70)
- Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. (2005) (69)
- Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis (2018) (69)
- Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma (2007) (69)
- Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. (2010) (67)
- Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents (2016) (67)
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis (2015) (66)
- Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation (2001) (66)
- Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia (2006) (66)
- Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. (2012) (66)
- Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib (2015) (66)
- Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience (2015) (66)
- Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. (2003) (65)
- Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006 (2011) (65)
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial (2011) (65)
- Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia (2003) (64)
- Reduction in C‐reactive protein indicates successful targeting of the IL‐1/IL‐6 axis resulting in improved survival in early stage multiple myeloma (2016) (64)
- Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia (2018) (63)
- Effect of complete response on outcome following autologous stem cell transplantation for myeloma (2000) (63)
- Bone marrow angiogenesis in multiple myeloma: effect of therapy (2002) (62)
- Second auto-SCT for treatment of relapsed multiple myeloma (2013) (62)
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. (2005) (62)
- Autologous stem cell transplantation for relapsed and primary refractory myeloma (1999) (62)
- Natural history of t(11;14) multiple myeloma (2017) (62)
- A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL) (2002) (61)
- Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma (2003) (61)
- Amyloidosis: diagnosis and management. (2005) (61)
- Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression (2017) (61)
- Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. (1999) (61)
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis (2014) (60)
- Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma (2007) (60)
- Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. (2012) (59)
- Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis (2016) (59)
- Ten‐year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis (2012) (59)
- Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia (2017) (59)
- Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia (2014) (59)
- A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing (2019) (59)
- Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. (2000) (59)
- Acquired Fanconi's syndrome associated with monoclonal gammopathies. (1999) (59)
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. (2011) (58)
- Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma (2004) (58)
- Therapy for immunoglobulin light chain amyloidosis: the new and the old. (2004) (57)
- Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death (2015) (57)
- Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. (2016) (57)
- Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma (2017) (56)
- Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome) (1997) (56)
- Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria (2018) (56)
- Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. (2010) (55)
- Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma (2006) (55)
- Autologous stem cell transplant for multiple myeloma patients 70 years or older (2016) (55)
- Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia (2001) (55)
- Long‐term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience (2016) (54)
- N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma (2016) (54)
- Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. (2002) (54)
- Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma (1999) (54)
- Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma (2010) (53)
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma (2018) (53)
- Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? (2018) (53)
- Pitfalls in the diagnosis of primary amyloidosis. (2010) (53)
- Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. (2016) (52)
- MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia (2018) (52)
- Transplantation for amyloidosis (2007) (51)
- Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma (2016) (51)
- Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. (2002) (50)
- Clinical course and prognosis of non‐secretory multiple myeloma (2015) (49)
- Serum uric acid: novel prognostic factor in primary systemic amyloidosis. (2008) (49)
- Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis (1999) (49)
- A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. (2001) (48)
- A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma (2005) (48)
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? (2013) (48)
- The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. (2017) (47)
- Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. (2006) (47)
- Outcomes of primary refractory multiple myeloma and the impact of novel therapies (2015) (45)
- Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-α in autologous stem cell transplantation (2001) (44)
- Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival. (2006) (44)
- Phase II trial of high‐dose dexamethasone for previously treated immunoglobulin light‐chain amyloidosis (1999) (44)
- Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature (2010) (43)
- Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. (2016) (43)
- Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. (2010) (43)
- Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis (2018) (43)
- Relationship between depth of response and outcome in multiple myeloma. (2007) (43)
- Induction therapy pre‐autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation (2016) (43)
- Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome (2010) (43)
- Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients (2012) (42)
- Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. (2006) (42)
- Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study (2012) (41)
- Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma (2000) (41)
- Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response (2020) (41)
- A phase II trial of imatinib in patients with refractory/relapsed myeloma (2006) (41)
- Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains (2018) (41)
- Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma (2018) (41)
- Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. (2020) (41)
- Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both (2015) (41)
- Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. (2007) (40)
- Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention (2010) (39)
- c‐erbB‐2 and p53 expression in fallopian tube carcinoma (1995) (39)
- Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma (2003) (39)
- Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. (2017) (39)
- Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. (2009) (39)
- Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease (2002) (39)
- Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. (2018) (39)
- Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis (2011) (38)
- Myelomatous Involvement of the Central Nervous System. (2016) (38)
- Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS. (2016) (38)
- Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma (1999) (37)
- Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. (2006) (37)
- Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. (2007) (37)
- Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition (2017) (37)
- Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. (2014) (37)
- Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma (1998) (37)
- Beta‐blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation (2016) (37)
- Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. (2000) (37)
- High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis (2001) (37)
- Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma (2015) (36)
- Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. (2005) (36)
- Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era (2016) (36)
- Dendritic cell-based treatment of cancer: closing in on a cellular therapy. (2001) (36)
- IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features (2019) (35)
- Impact of acquired del(17p) in multiple myeloma. (2019) (35)
- Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma (1999) (35)
- Response to rituximab in patients with type II cryoglobulinemia. (2006) (35)
- Continued improvement in survival in multiple myeloma (MM) including high-risk patients. (2019) (34)
- Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T (2015) (34)
- Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio (2018) (34)
- Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. (2013) (34)
- Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes (2020) (34)
- Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival (2017) (33)
- Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. (2005) (33)
- Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation. (2012) (32)
- Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern (2019) (32)
- Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. (1999) (32)
- Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light‐chain amyloidosis (2016) (32)
- Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (2013) (32)
- Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis (2019) (32)
- Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy (2014) (32)
- Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. (2013) (31)
- Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis (2020) (31)
- Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias (2014) (30)
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. (2001) (30)
- Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma (2017) (30)
- Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents (2012) (30)
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma (2013) (30)
- Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma (2015) (30)
- Thalidomide plus dexamethasone (thal/dex) and thalidomide alone (thal) as first line therapy for newly diagnosed myeloma (mm) (2000) (30)
- Acute lung toxicity related to pomalidomide. (2011) (29)
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome (2017) (29)
- Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation (2018) (29)
- A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis. (2009) (29)
- Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. (2015) (28)
- Localized AL amyloidosis of the colon: an unrecognized entity (2003) (28)
- Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma. (2009) (28)
- Long‐term results of single‐agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma (2010) (28)
- Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. (2005) (28)
- Ploidy status rarely changes in myeloma patients at disease progression. (2006) (28)
- Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors (2017) (28)
- Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis (2010) (27)
- Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival (2017) (27)
- A Phase II study of 153Sm‐EDTMP and high‐dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma (2010) (27)
- Clinical characteristics and outcomes in biclonal gammopathies (2016) (27)
- Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells (2019) (27)
- Primary systemic amyloidosis in patients with Waldenström macroglobulinemia (2018) (27)
- The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents (2017) (27)
- Venetoclax for the treatment of translocation (11;14) AL amyloidosis (2020) (26)
- Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist (2015) (26)
- Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials (2017) (26)
- Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance (2018) (26)
- Natural history of multiple myeloma with de novo del(17p) (2019) (26)
- Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT (2013) (26)
- Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis (2020) (25)
- Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years (2008) (25)
- Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment (2016) (25)
- Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. (2004) (25)
- IL-1β expression in IgM monoclonal gammopathy and its relationship to multiple myeloma (2002) (25)
- Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation (2017) (25)
- Natural history of thromboembolism in AL amyloidosis (2006) (25)
- Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis (2019) (24)
- Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. (2008) (24)
- Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT (2008) (24)
- Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis (2020) (24)
- The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma (2005) (24)
- Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist (2013) (24)
- Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma (2012) (23)
- The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. (2016) (23)
- Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis (2017) (23)
- Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma (2008) (23)
- Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. (2017) (22)
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma (2008) (22)
- Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis (2007) (22)
- Venetoclax For The Treatment of Translocation AL Amyloidosis (2019) (22)
- Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM). (2004) (22)
- Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia (2017) (21)
- Implications of continued response after autologous stem cell transplantation for multiple myeloma. (2013) (21)
- Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. (2018) (21)
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. (2016) (21)
- Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light‐chain amyloidosis (2012) (20)
- Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis (2008) (20)
- High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma (2006) (20)
- Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. (2009) (20)
- Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy (2013) (20)
- Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials (2013) (20)
- Veno-occlusive Disease of the Liver after Blood and Marrow Transplantation: Analysis of Pre- and Post-transplant Risk Factors Associated with Severity and Results of Therapy with Tissue Plasminogen Activator (2002) (20)
- Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia (2018) (19)
- Utility and prognostic value of 18F‐FDG positron emission tomography‐computed tomography scans in patients with newly diagnosed multiple myeloma (2018) (19)
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant (2014) (19)
- Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy (1998) (19)
- Autologous stem cell transplantation and IgM amyloidosis (2006) (19)
- Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. (2018) (19)
- A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis (2020) (19)
- Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib (2013) (19)
- Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse (2018) (19)
- Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation (2015) (19)
- MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients (2021) (19)
- Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. (2017) (19)
- Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders (2008) (19)
- Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis (2020) (18)
- Factors influencing platelet recovery after blood cell transplantation in multiple myeloma (1997) (18)
- Mortality trends in multiple myeloma after the introduction of novel therapies in the United States (2021) (18)
- Revisiting complete response in light chain amyloidosis (2019) (18)
- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (2018) (18)
- Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation (2017) (18)
- Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia (2019) (18)
- Comparative analysis of staging systems in AL amyloidosis (2018) (18)
- Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation (2001) (17)
- Peripheral blood stem cell transplant (PBSCT) in a large series of patients with poems syndrome (2004) (17)
- “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience (2021) (17)
- Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma (2015) (17)
- Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. (2021) (17)
- SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization (2011) (17)
- Evaluation of pretransplant factors predicting cardiac dysfunction following high‐dose melphalan conditioning and autologous peripheral blood stem cell transplantation (2012) (17)
- Serum M‐spike and transplant outcome in patients with multiple myeloma (2007) (17)
- First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. (2016) (17)
- Multiple myeloma after kidney transplantation (2015) (17)
- Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma (2016) (17)
- Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2) (2010) (17)
- Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis (2010) (17)
- A phase ii trial of thalidomide in the treatment of relapsed multiple myeloma (mm) with laboratory correlative studies (2000) (16)
- Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis (2019) (16)
- Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. (2019) (16)
- Immunoglobulin D amyloidosis: a distinct entity. (2012) (16)
- Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma (2018) (16)
- Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis (2019) (16)
- A novel report of cig‐FISH and cytogenetics in POEMS syndrome (2008) (16)
- Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy (2016) (16)
- Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma (2020) (16)
- Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis (2017) (16)
- Hematology patient reported symptom screen to assess quality of life for AL amyloidosis (2017) (16)
- Immunoglobulin Variable Light Chain Restriction, Cytokine Expression and Plasma Cell-Stromal Cell Interactions in POEMS Syndrome Patients (2008) (15)
- Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. (2018) (15)
- Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma (2018) (15)
- CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies (2010) (15)
- A simple additive staging system for newly diagnosed multiple myeloma (2022) (15)
- Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio (2020) (15)
- Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. (2018) (15)
- Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies (2012) (15)
- Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis (2019) (15)
- Pomalidomide therapy for multiple myeloma and myelofibrosis: an update (2011) (15)
- Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials (2019) (14)
- Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma (2020) (14)
- Time to plateau as a predictor of survival in newly diagnosed multiple myeloma (2018) (14)
- Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (2019) (14)
- Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma. (2007) (13)
- Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma (2018) (13)
- Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation (2018) (13)
- Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI). (2013) (13)
- Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia (2018) (13)
- Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma (2012) (13)
- Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma (2016) (13)
- Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial (2018) (13)
- Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years, (2011) (12)
- Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma (2020) (12)
- Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients (2007) (12)
- Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systemic Amyloidosis, but Responses Are Limited. (2004) (12)
- Impact of additional cytoreduction following autologous SCT in multiple myeloma (2008) (12)
- Incidence and Survival Outcomes Of Extramedullary Myeloma (2013) (12)
- Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma (2017) (12)
- Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. (2020) (12)
- Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL) (2018) (12)
- New Immunomodulatory Drugs in Myeloma (2011) (12)
- Disseminated nocardiosis after allogeneic bone marrow transplantation (1997) (12)
- Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy (2012) (12)
- Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients (2019) (11)
- Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis. (2006) (11)
- Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma (2022) (11)
- A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization (2010) (11)
- Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type (2016) (11)
- Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma (2018) (11)
- Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib (2015) (11)
- Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study. (2019) (11)
- Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents (2020) (11)
- Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia (2020) (11)
- Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation (2020) (11)
- Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma (2020) (10)
- Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. (2005) (10)
- Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. (2021) (10)
- Prophylaxis of graft-versus-host disease with cyclosporine–prednisone is associated with increased risk of chronic graft-versus-host disease (2001) (10)
- In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO) (2015) (10)
- A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma (2017) (10)
- Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi‐parametric flow cytometry method (2019) (10)
- Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma (2013) (10)
- Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma (2011) (10)
- Post-transplant complications High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis (2001) (10)
- Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma (2018) (10)
- Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. (2015) (10)
- Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT (2014) (10)
- A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls. (2007) (10)
- Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score (2010) (10)
- Substratification of patients with newly diagnosed standard‐risk multiple myeloma (2019) (10)
- A Risk Adapted Approach Utilizing Plerixafor in Autologous Peripheral Blood Stem Cell Mobilization. (2009) (10)
- Utility of serum free light chain ratio in response definition in patients with multiple myeloma. (2020) (10)
- Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. (2013) (9)
- Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma (2010) (9)
- Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma (2013) (9)
- Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis (2010) (9)
- Natural history of amyloidosis isolated to fat and bone marrow aspirate (2015) (9)
- Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients (2020) (9)
- Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia (2021) (9)
- Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS) (2019) (9)
- Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL) (2007) (9)
- Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis (2019) (9)
- Population pharmacokinetics of CP-751,871, a monoclonal antibody against IGF-I receptor, in patients with multiple myeloma or solid tumors (2008) (9)
- Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM) (2013) (9)
- MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) (2013) (9)
- Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation (2018) (9)
- Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study (2004) (9)
- First report of MYD88L265P somatic mutation in IgM-associated light chain amyloidosis (2017) (8)
- High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma (2008) (8)
- Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma. (2005) (8)
- Cytogenetic analysis using multiple myeloma targets in POEMS syndrome (2007) (8)
- Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM). (2016) (8)
- Long Term Follow-up of Patients with Immunoglobulin Light Chain Amyloidosis Treated with Lenalidomide and Dexamethasone. (2008) (8)
- Thalidomide and dexamethasone in newly diagnosed multiple myeloma: Long-term results in patients not undergoing upfront autologous stem cell transplantation (2005) (8)
- Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma (2020) (8)
- Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma (2019) (8)
- Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor. (2006) (8)
- Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. (2020) (8)
- Arterial thrombosis complicates myeloma? (2010) (8)
- A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis (2010) (8)
- Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. (2018) (8)
- Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia (2021) (7)
- Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria (2019) (7)
- Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis (2019) (7)
- Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function (2019) (7)
- Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy (2019) (7)
- Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. (2019) (7)
- Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (2008) (7)
- Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. (2019) (7)
- Response: pure red blood cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. (1996) (7)
- Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. (2015) (7)
- Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma (2014) (7)
- Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006 (2011) (7)
- Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma (2010) (7)
- Dendritic cell-based idiotype vaccination for primary systemic amyloidosis (2000) (7)
- Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation (2015) (7)
- Assessment of the Need for a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Using a Needs-Based Survey. (2019) (7)
- A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients. (2009) (7)
- Venetoclax for the treatment of translocation (11;14) AL amyloidosis (2019) (7)
- Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients (2021) (6)
- Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy (2021) (6)
- A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma (2013) (6)
- Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience (2015) (6)
- Severe Reversible Pulmonary Hypertension in Smoldering Multiple Myeloma: Two Cases and Review of the Literature (2015) (6)
- Pure red cell aplasia (1996) (6)
- Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma (2017) (6)
- Prognostic Significance of Circulating Plasma Cells by Multi-Parametric Flow Cytometry in Light Chain Amyloidosis (2018) (6)
- Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma (2014) (6)
- Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization (2011) (6)
- In vivo and in silico studies on single versus multiple transplants for multiple myeloma (2007) (6)
- Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design (2021) (6)
- Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. (2019) (6)
- Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies (2011) (6)
- A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia. (2009) (6)
- Myelomatous Involvement of the Central Nervous System: Mayo Clinic Experience (2013) (6)
- Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis (2010) (6)
- The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. (2021) (6)
- Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival (2016) (6)
- Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete response (sCR) following upfront autologous stem cell transplantation (SCT). (2011) (6)
- Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation. (2016) (6)
- The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? (2019) (6)
- Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma (2019) (6)
- Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response (2018) (6)
- Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency (2016) (6)
- Acute cellular rejection in a renal allograft immediately following leukocyte engraftment after auto-SCT (2009) (6)
- Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation (2008) (6)
- Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series. (2021) (6)
- Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma (2022) (5)
- Lymphoid reconstitution Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia (2001) (5)
- Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis (2022) (5)
- Daratumumab-based therapies in patients with AL amyloidosis. (2018) (5)
- Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting (2016) (5)
- Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort (2021) (5)
- Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis) (2013) (5)
- Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation (2018) (5)
- The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma (2019) (5)
- Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM). (2019) (5)
- Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation. (2009) (5)
- Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort (2011) (5)
- Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma (2021) (5)
- Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma. (2007) (5)
- The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM) (2021) (5)
- In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders. (2005) (5)
- Coagulation Abnormalities in Light Chain Amyloidosis. (2021) (5)
- Outcome after second stem cell transplantation for relapsed multiple myeloma (2007) (5)
- Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM). (2010) (5)
- Outcome of very young (≤40 years) patients with immunoglobulin light chain (AL) amyloidosis (2017) (5)
- Outcomes with High Dose Therapy and Peripheral Blood Stem Cell Transplantation for Light Chain (AL) Amyloidosis with Cardiac Involvement. (2009) (5)
- Inhibition of the insulin like growth factor 1 receptor by a specific monoclonal antibody in multiple myeloma (2005) (5)
- Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma (2009) (5)
- Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma (2022) (5)
- Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM) (2020) (5)
- Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation (2020) (5)
- Analysis of Outcome after Autologous Stem Transplantation in Patients with Newly Diagnosed Myeloma: Comparison of Different Induction Regimens. (2006) (5)
- Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. (2009) (4)
- Prognostic restaging after treatment initiation in patients with AL amyloidosis. (2020) (4)
- Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis (2018) (4)
- Characterization and prognostic implication of delayed complete response in AL amyloidosis (2020) (4)
- Phase I Trial of Autologous Hematopoietic Stem Cell Transplantation with Escalating Doses of Topotecan Combined with Cyclophosphamide and Carboplatin in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma (2009) (4)
- Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. (2020) (4)
- Combining Measurements of Plasma Cell Apoptosis and Proliferation in Multiple Myeloma Identifies Patients with Poor Survival. (2005) (4)
- TEMPI: A Reversible Syndrome Following Treatment with Bortezomib (2012) (4)
- Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis. (2005) (4)
- Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma (2006) (4)
- Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant (2015) (4)
- Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. (2021) (4)
- Acquired intracoronary ADAMTS 13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI (2016) (4)
- Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (4)
- Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation (2018) (4)
- Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. (2018) (4)
- 17p Deleted Multiple Myeloma: Clinical Outcomes and Predictive Factors For Acquisition Of 17p Deletion (2013) (4)
- Increasing the Number of Apheresis Collections Increases Lymphocyte Collection and Affects Survival after Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. (2004) (4)
- Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome (2008) (4)
- Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100 (2021) (4)
- Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma (2009) (4)
- Improvement In Renal Function In Newly Diagnosed Myeloma Improves Survival, but Still Remains Inferior to Those with Normal Renal Function (2010) (4)
- A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis. (2010) (4)
- Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. (2012) (4)
- Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis (2016) (4)
- Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis (2021) (4)
- Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis (2020) (4)
- Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma (2020) (4)
- Autologous Stem Cell Transplantation for Multiple Myeloma in Patients over 70 Years: A Matched Comparison with Patients under 65 Years. (2005) (4)
- Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant (2020) (4)
- A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma. (2009) (4)
- A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM). (2010) (4)
- Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis (2019) (4)
- Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients (2021) (4)
- Serum free light chain measurements to reduce 24‐h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein (2018) (4)
- Second stem cell transplantation for relapsed refractory light chain (AL) amyloidosis. (2021) (3)
- A Phase II Trial of Gleevec™ in Patients with Refractory/Relapsed Myeloma. (2004) (3)
- Residual serum monoclonal protein predicts progression‐free survival in patients with previously untreated multiple myeloma (2010) (3)
- Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM). (2016) (3)
- Thalidomide plus dexamethasone in newly diagnosed multiple myeloma (2006) (3)
- Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney (2008) (3)
- "IM iD"eally treating multiple myeloma. (2013) (3)
- Changes in Serum Free Light Chain Rather Than Intact Monoclonal Immunoglobulin Levels Predict Outcome with Therapy in Patients with Light Chain Amyloidosis. (2009) (3)
- Multiple myeloma: new options, new challenges. (2006) (3)
- The Role of Stem Cell Mobilization Regimen on Lymphocyte Collection Yield and Survival after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. (2005) (3)
- Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab (2022) (3)
- Second autologous stem cell transplantation as a strategy for management of relapsed multiple myeloma. (2012) (3)
- Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis (2021) (3)
- Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis (2013) (3)
- The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma (2017) (3)
- Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma. (2005) (3)
- PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma (2014) (3)
- Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma (2021) (3)
- Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention. (2009) (3)
- Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (2011) (3)
- Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. (2021) (3)
- A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement. (2009) (3)
- Depth of response with stem cell transplantation and outcome for multiple myeloma in the era of novel agents (2010) (3)
- Influence of Obesity on Outcomes of Patients with Relapsed Refractory Multiple Myeloma (2017) (3)
- Outcomes of young patients with Waldenstrom macroglobulinemia (WM). (2014) (3)
- Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy. (2004) (3)
- Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM). (2016) (3)
- Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancy (2008) (3)
- Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM) (2016) (3)
- Predictors of short-term survival in Waldenström Macroglobulinemia (2020) (3)
- Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma (2013) (3)
- Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. (2013) (3)
- Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma (2019) (3)
- Improving Survival in Multiple Myeloma: Impact of Novel Therapies. (2007) (3)
- The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? (2020) (3)
- Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting (2018) (3)
- Clinical activity of systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma. (2021) (3)
- Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer (2018) (3)
- Association of translocation t(11;14) with survival in patients with light chain (AL) amyloidosis (2008) (3)
- Toxicities associated with stem cell mobilization utilizing cyclophosphamide and growth factor versus G-CSF alone in primary systemic amyloidosis (2000) (3)
- Excessive Weight Gain during Mobilization Increases First Year Mortality Following High Dose Therapy and Stem Cell Transplantation in Patients with Primary Amyloidosis. (2004) (3)
- Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma (2012) (3)
- Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience (2016) (3)
- Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. (2020) (3)
- Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia (2020) (3)
- Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B. (2005) (2)
- Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM) (2020) (2)
- Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome (2022) (2)
- Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome. (2019) (2)
- Risk Factors of Treatment Related Mortality during Autologous Stem Cell Transplant in Patients with Light Chain Associated Amyloidosis (AL). (2006) (2)
- Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis (2017) (2)
- Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents (2013) (2)
- Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis (2012) (2)
- Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis (2020) (2)
- Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis (2020) (2)
- Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients (2010) (2)
- A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM) (2011) (2)
- 1D09C3, A NOVEL APOPTOTIC HUMAN MONOCLONAL ANTI- BODY: MODE OF ACTION AFFECTS DOSING SCHEDULES* (2005) (2)
- MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients (2020) (2)
- Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis (2021) (2)
- Implications and outcomes of MRD‐negative multiple myeloma patients with immunofixation positivity (2019) (2)
- The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients That Are "Poor Responder" to Induction- The Mayo Clinic Experience. (2021) (2)
- Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010. (2014) (2)
- Quality of Life and Outcomes in Multiple Myeloma Patients (2014) (2)
- Fluid-Related Complications in Patients with Amyloidosis Associated with Filgrastim during Peripheral Blood Stem Cell Mobilization. (2004) (2)
- Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia (2016) (2)
- Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis (2017) (2)
- Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma (2020) (2)
- Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage (2016) (2)
- Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM) (2012) (2)
- Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM). (2017) (2)
- Depth of Response with Stem Cell Transplantation and Outcome for Multiple Myeloma in the Era of Novel Agents. (2009) (2)
- Outcomes after biochemical or clinical progression in patients with multiple myeloma (2022) (2)
- Upstaging the R-ISS classification of newly diagnosed multiple myeloma (NDMM) patients (pts) by quantifying circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC). (2019) (2)
- Cardiomyopathy Following High Dose Melphalan Conditioning Prior to Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma and Primary Amyloidosis (2011) (2)
- Use of the Serum Free Light Chain Assay in Assessment of Response to Therapy in Multiple Myeloma: Validation of Recently Proposed Response Criteria in a Prospective Clinical Trial of Lenalidomide Plus Dexamethasone for Newly Diagnosed Multiple Myeloma. (2005) (2)
- Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL) (2018) (2)
- Salvage autologous stem cell transplant is an effective regimen for relapsed multiple myeloma (2013) (2)
- Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003) (2013) (2)
- A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome (2019) (2)
- Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant (2012) (2)
- A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289) (2010) (2)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
- Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease (2010) (2)
- Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing (2014) (2)
- Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience. (2007) (2)
- Powerful Risk Stratification in Patients with AL Using Serum Cardiac Biomarkers. (2005) (2)
- Long‐term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy (2014) (2)
- Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma (2021) (2)
- The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma (2020) (2)
- Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003. (2013) (2)
- Therapeutic Strategies For Initial Treatment Of AL Amyloidosis: Implications Of Therapy and Response On Outcome (2013) (2)
- Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison. (2006) (2)
- Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States (2019) (2)
- Analysis of B cell clonal evolution in BM and PBL of AL and MM patients using graphical quantification of lineage trees (2004) (2)
- Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma (2019) (2)
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma (2018) (2)
- Survival Outcomes Of Very Young (<40 years) Myeloma Patients (2013) (2)
- Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis (2020) (2)
- Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis. (2012) (2)
- TCL-461: Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Relapsed Refractory Hematologic Malignancies (2021) (2)
- Early Immunoglobulin Free Light Chain (FLC) Response Post Autologous Peripheral Blood Stem Cell Transplant Predicts for Hematologic Complete Response in Patients with Multiple Myeloma. (2006) (2)
- Melphalan and Dexamethasone Is Less Effective for Patients with Immunoglobulin Light Chain Amyloidosis (AL) with High Bone Marrow Plasmacytosis. (2008) (2)
- Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma. (2009) (2)
- Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis (2016) (1)
- Factors predicting organ response in light chain amyloidosis (AL). (2017) (1)
- Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis (2016) (1)
- Outcomes of patients with primary plasma cell leukemia (pPCL) in the era of novel agent therapy. (2020) (1)
- Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis. (2007) (1)
- A 66-year-old woman with an enlarged tongue (2013) (1)
- Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM). (2022) (1)
- Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy (2019) (1)
- Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition. (2017) (1)
- Plasma cell disorders (2013) (1)
- Current status of stem cell transplantation for multiple myeloma (2005) (1)
- Holistic review for hematology‐oncology fellowship applicants: A new paradigm? (2020) (1)
- Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma (2014) (1)
- Disparities in Outcomes of Patients with Multiple Myeloma Based on Geographic Distance from NCI-Designated Cancer Centers: A SEER Based Analysis (2017) (1)
- Depth of Response in Waldenstrom Macroglobulinemia (2018) (1)
- Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis (2019) (1)
- Prognostic significance of acquired 1q22 gain in multiple myeloma. (2021) (1)
- Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation (2009) (1)
- The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma. (2004) (1)
- Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma. (2004) (1)
- The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents (2015) (1)
- Analysis of the Immunoglobulin Heavy and Light Chain Gene Expression and Mutations in POEMS Patients. (2009) (1)
- Time Interval from Last Chemotherapy to Stem Cell Collection Correlates with Peripheral Blood Absolute Lymphocyte Count at Apheresis and Survival Post-Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma. (2004) (1)
- Comparison of High-Dose Cyclophosphamide and Growth Factor with Growth Factor Alone for Mobilization of Stem Cells for Transplantation in Patients with Multiple Myeloma. (2008) (1)
- Myeloma International Staging System Retains Its Prognostic Value at Disease Relapse. (2007) (1)
- Predictors of Hyperviscosity Syndrome (HVS) in Waldenström Macroglobulinemia (WM) (2017) (1)
- Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma (2018) (1)
- Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant (2019) (1)
- Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma (2018) (1)
- Cardiac troponins and N-terminal pro-brain natriuretic peptide predict survival in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant (2004) (1)
- Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?. (2007) (1)
- Early Paraprotein Kinetics and Response to Treatment in Multiple Myeloma (2017) (1)
- Retroperitoneal involvement with light chain amyloidosis- case series and literature review (2020) (1)
- Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients (2020) (1)
- Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation (2022) (1)
- Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation (2020) (1)
- Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma (2013) (1)
- CARDIAC TRANSPLANTATION IN IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS: A LARGE SINGLE CENTER EXPERIENCE (2014) (1)
- What Does AL Amyloidosis Look like in the Era of Mass Spectrometry Typing (2017) (1)
- 14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH). (2007) (1)
- Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation (2020) (1)
- Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance (2022) (1)
- Eligibility f or H ematopoietic S tem-Cell T ransplantation for P rimary S ystemic A myloidosis I s a F avorable Prognostic F actor f or S urvival (2001) (1)
- Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses (2014) (1)
- Novel therapy with 2-methoxyestradiol (2ME2) for the treatment of relapsed and plateau phase multiple myeloma (2007) (1)
- Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma—a Single Center Experience (2017) (1)
- Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis (2020) (1)
- Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis (2016) (1)
- Depth of Organ Response in Newly Diagnosed AL Amyloidosis Is Associated with Improved Survival: Improved Outcome Discrimination with Graded Organ Response (2017) (1)
- Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS) (2021) (1)
- Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression. (2016) (1)
- A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial. (2014) (1)
- Measurement of the Proliferation of Clonal Plasma Cells By Multiparametric Flow Cytometry Is a Clinically Useful Tool in Multiple Myeloma (2014) (1)
- A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin (2013) (1)
- 6q Deletion in Waldenström Macroglobulinemia Is the Most Common Cytogenetic Abnormality and Is Associated with Aggressive Disease with a Trend towards Worse Survival. (2005) (1)
- Does stage migration exist in active multiple myeloma (MM) (2012) (1)
- Outcomes of Autologous Hematopoietic Stem Cell Transplant in Sporadic Late Onset Nemaline Myopathy with Associated Monoclonal Gammopathy of Unknown Significance (2018) (1)
- Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis (2016) (1)
- Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma (2019) (1)
- Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide (2020) (1)
- Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma (2022) (1)
- Second- and third-line treatment strategies in multiple myeloma: a referral-center experience (2022) (1)
- The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis (2011) (1)
- IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features (2018) (1)
- Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type (2017) (1)
- Retrospective Study of the Efficacy of Bortezomib in Primary Systemic Amyloidosis. (2009) (1)
- Peripheral Blood CD34 Count Can Predict Successful Progenitor Cell Mobilization in Poor Mobiliziers Treated With Plerixafor and G-CSF (2009) (1)
- Immunophenotypic and molecular comparison between allogeneic and autologous graft‐vs‐host disease of the skin: A retrospective study using immunohistochemical and proteomics methods (2017) (1)
- Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM) (2016) (1)
- Paravertebral Waldenström's macroglobulinaemia presenting as pseudoclaudication (2011) (1)
- Early prediction of relapse after allogenic transplant for acute myelogenous leukemia (2000) (1)
- Chemotherapy-based stem cell mobilization in multiple myeloma patients treated with novel agents: The Mayo Clinic experience. (2021) (1)
- Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component (2011) (1)
- Stem Cell Mobilization In Patients With Newly Diagnosed Multiple Myeloma Following Therapy With Lenalidomide and Dexamethasone (2009) (1)
- Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment (2020) (1)
- Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma q (2007) (1)
- The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma (2019) (1)
- Pomalidomide (Blood (2013) 122, 14 (2305-2309)) (2014) (1)
- Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience. (2019) (1)
- Prognostic Impact of CD3 Count in Apheresis Collection in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant (2021) (1)
- Systemic AL Amyloidosis Myopathy: Presentation, Diagnostic Pitfalls and Outcome (2016) (1)
- Sequential Heart and Autologous Stem Cell Transplantation for AL Amyloidosis. (2006) (1)
- Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma. (2006) (1)
- Ruxolitinib Rescues Mice from Lethal Interferon Beta Toxicity and TLS (2017) (1)
- Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes (2015) (1)
- Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model (2018) (1)
- Supportive Care for Amyloidosis (2010) (1)
- Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma. (2013) (1)
- Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM). (2016) (1)
- Baseline Serum Albumin and Proteinuria Predict Renal Response after Autologous Stem Cell Transplantation in AL Amyloidosis. (2005) (1)
- Long-Term Outcomes of IMiD Based Trials in Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Pooled Analysis (2017) (1)
- Belantamab mafodotin detection by MASS-FIX and immunofixation (2021) (1)
- Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma. (2009) (1)
- MYOCARDIAL CONTRACTION FRACTION, A NEW ECHOCARDIOGRAPHIC PARAMETER FOR PREDICTION OF SURVIVAL IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS (2016) (1)
- A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH (2019) (1)
- Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial. (2011) (1)
- Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant (2022) (1)
- Pomalidomide - An appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma (2015) (1)
- P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE (2022) (1)
- Extent of Hematologic Response is Important in Determining Outcome in Transplanted Patients with Primary Systemic Amyloidosis. Importance of Achieving a Complete Response (2007) (1)
- Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies (2011) (1)
- Analysis and Outcomes of Non-Utilization of Collected Peripheral Blood Stem Cell (PBSC) for Autologous Stem Cell Transplants (ASCT) in Transplant Eligible Patients Undergoing Treatment of Multiple Myeloma (MM) (2017) (1)
- Combined High Resolution Array Comparative Genomic Hybridization and Gene Expression Profiling Reveal Rb1 Haploinsufficiency as a Possibile Tumorigenic Mechanism in Myeloma. (2006) (1)
- Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma. (2012) (1)
- A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma (2009) (1)
- Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT). (2009) (1)
- 100 Long Term Outcome of Renal Failure in Multiple Myeloma Following Autologous Stem Cell Transplant (2011) (1)
- Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes (2020) (1)
- Mayo Clinic Hematology Fellowship for Advanced Practice Providers (2020) (1)
- Phase 1/2 Trial of Carfilzomib and Melphalan Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL) (2019) (1)
- COMPARABLE OUTCOMES IN NON-SECRETORY AND SECRETORY MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (2009) (0)
- Delayed resolution of nephrotic syndrome following stem cell transplant for amyloidosis (al) (2004) (0)
- Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma. (2018) (0)
- light-chain amyloidosis: long-term results from a phase 2 trial Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for (2012) (0)
- Allogeneic HSC Transplantation for Multiple Myeloma: A Single Institution Experience. (2007) (0)
- Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. (2012) (0)
- A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM) (2015) (0)
- Azithromycin For Bronchiolitis Obliterans Following Allogeneic Hematopoietic Stem Cell Transplantation (2010) (0)
- Clinical Features and Treatment Response of Light Chain ( AL ) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma original articl (0)
- Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma (2022) (0)
- Extent of Hematologic Response Is Important in Determining Outcome in Transplanted Patients with Primary Amyloidosis AL. Importance of Achieving CR. (2006) (0)
- Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience (2011) (0)
- The Hari/Pasquini/Vesole article reviewed (2006) (0)
- The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics. (2016) (0)
- Use of Maintenance Therapy Post Autologous Stem Cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience (2019) (0)
- Bortezomib Versus Non-Bortezomib Based Initial Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis (2017) (0)
- Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light chain amyloidosis (2008) (0)
- The Serum M-Spike and Transplant Outcome in Patients with Multiple Myeloma. (2006) (0)
- A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders (2020) (0)
- Survival in Primary SyStemic amyloidoSiS (2010) (0)
- Outcomes with different administration schedules of VRD as first-line therapy in multiple myeloma: a retrospective analysis (2019) (0)
- The use of proteasome inhibitors among patients with POEMS syndrome. (2017) (0)
- Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches (2010) (0)
- Higher CD3 cell counts in apheresis collection in relation to superior survival in patients with multiple myeloma. (2015) (0)
- Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival (2018) (0)
- The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma (2021) (0)
- Treatment of Diuretic Refractory Pleural Effusions with Bevacizumab in Four Patients with Primary Systemic Amyloidosis (AL). (2006) (0)
- Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma (2022) (0)
- Definition of a high-risk population among patients with AL amyloidosis not undergoing autologous stem cell transplantation using bone marrow plasmacytosis and the presence of CRAB. (2013) (0)
- Comparable Outcomes in Secretory (SM) Versus Non-Secretory (NSM) Multiple Myeloma (MM) with Autologous Hematopoietic Stem Cell Transplantation (AuHCT). (2007) (0)
- Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis (2022) (0)
- Acquired Fanconi Syndrome Associated With Monoclonal Plasma Cell Disorders (2004) (0)
- Implications of a Rising Serum Monoclonal Protein and Free Light Chains Post Autologous Stem Cell Transplant in Patients with Multiple Myeloma (2020) (0)
- P-246: Impact of defining refractoriness vs lines of therapy in relapsed/refractory multiple myeloma (2022) (0)
- Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment (2018) (0)
- Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category (2016) (0)
- Prognostic Value of Bone Marrow Angiogenesis in Newly Diagnosed Multiple Myeloma: A Comparison with Conventional Prognostic Factors. (2005) (0)
- Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Transplanted for Multiple Myeloma. (2005) (0)
- Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation. (2017) (0)
- PET Imaging of a Unique Case of Multiple Myeloma in an Adolescent. (2020) (0)
- Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma (2015) (0)
- Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes (2020) (0)
- Prognostic Significance of Baseline High Risk Features during Follow-up in Immunoglobulin Light Chain Amyloidosis (2017) (0)
- Measures of immune recovery following autologous stem cell transplantation for multiple myeloma and outcome. (2013) (0)
- Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome (2021) (0)
- The combination of thalidomide and dexamethasone results in response rates of 40 – 50 % in relapsed MM (2013) (0)
- Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma (2018) (0)
- Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2022) (0)
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria (2018) (0)
- Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma (2022) (0)
- Cytokine Levels In Patients With Plasma Cell Disorders (PCD) Undergoing Peripheral Blood Stem Cell Transplant (PBSCT) (2010) (0)
- non-hyperdiploid variant multiple myeloma The recurrent IgH translocations are highly associated with (2013) (0)
- Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance (2022) (0)
- Predictors of disease progression in smoldering Waldenström macroglobulinemia. (2018) (0)
- Overt Multiple Myeloma Acquired Fanconi Syndrome Is an Indolent Disorder in the Absence of (2013) (0)
- The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma. (2017) (0)
- Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation. (2006) (0)
- Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis (2021) (0)
- IgD Amyloidosis: An Unrecognized Entity (2011) (0)
- Thalidomide Based Induction Chemotherapy Prior to Stem Cell Transplantation in Myeloma Is Associated with Decreased Response to Retreatment with Thalidomide at First Relapse Post Transplant. (2007) (0)
- Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients (2014) (0)
- Outcomes and treatment of patients with POEMS syndrome experiencing progression or relapse after first line treatment. (2015) (0)
- Prognostic Value of Serum Lactate Dehydrogenase (LDH) in Patients with Primary Systemic Amyloidosis Undergoing Stem Cell Transplantation. (2007) (0)
- Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis. (2020) (0)
- The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up. (2022) (0)
- Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma. (2016) (0)
- Autologous Stem Cell Transplantation in Patients with Autonomic Neuropathy Due to AL Amyloidosis (2008) (0)
- Clinically significant delay in engraftment with day -1 melphalan prior to stem cell infusion in myeloma patients receiving stem cell transplant. (2019) (0)
- Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14) (2019) (0)
- A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies (2009) (0)
- MM-203: Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation (2020) (0)
- Predictors of Survival in Multiple Myeloma Patients after Relapse from a Delayed Autologous Stem Cell Transplant (2015) (0)
- Continued M Protein Responses Beyond Day 100 After Autologous Transplantation for Myeloma: Implications for Post Transplant Strategies (2009) (0)
- Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience. (2004) (0)
- Comparison of Different Techniques to Identify Cardiac Involvement in Immunoglobulin Light Chain Amyloidosis (2018) (0)
- Should Troponin Level Be an Exclusion Criterion for Stem Cell Transplantation in Primary Amyloidosis (2007) (0)
- The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma (2021) (0)
- Prospective R andomized T rial o f M elphalan a nd P rednisone Versus V incristine, C armustine, M elphalan, Cyclophosphamide, a nd P rednisone i n t he T reatment of P rimary S ystemic A myloidosis (1999) (0)
- Impact of metformin use in the outcomes of multiple myeloma patients post stem cell transplant. (2017) (0)
- Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma. (2016) (0)
- Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy (2011) (0)
- IgH translocations are common in patients with primary systemic amyloidosis (al) (2000) (0)
- Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population (2018) (0)
- Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma (2018) (0)
- Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma (2020) (0)
- Implications of rapidity of response to initial therapy in multiple myeloma. (2013) (0)
- Clinical Outcome of IgM Amyloidosis (AL) Following Stem Cell Transplantation. (2005) (0)
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma. (2015) (0)
- early genetic events in patients with primary systemic amyloidosis Translocations involving the immunoglobulin heavy-chain locus are possible (2011) (0)
- Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes. (2016) (0)
- Unraveling Early Mortality In Patients with AL Amyloidosis (2010) (0)
- New Questions About Transplantation in Multiple Myeloma: Review 2 (2006) (0)
- P-140: Monoclonal proteinuria ≥200 mg/24h predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100 (2021) (0)
- ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCITrial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models. (2014) (0)
- Autologous stem cell transplantation for multiple myeloma in patients over 70 years: A matched comparison with patients under 65 years (2006) (0)
- Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation (2020) (0)
- Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy (2022) (0)
- The Impact of Proliferating Polyclonal Plasma Cells on Outcome after Autologous Stem Cell Transplantation in Multiple Myeloma (2020) (0)
- NovelTherapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau PhaseMultiple Myeloma (2007) (0)
- Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma (2010) (0)
- Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM). (2009) (0)
- Predictors for “Poor Mobilizers” After Cyclophosphamide Mobilization in Multiple Myeloma (2011) (0)
- Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden (2016) (0)
- Characterization of Long-Term Multiple Myeloma Survivors (2018) (0)
- 87: Peripheral Blood Stem Cell Transplant for POEMS Syndrome is Associated with High Rates of Engraftment Syndrome (2008) (0)
- 255: Rescue Mobilization of Hematopoietic Progenitor Cells with AMD3100 + G-CSF is Successful in Patients Who Previously Failed Mobilization (2008) (0)
- Pomalidomide (2018) (0)
- Beneficial effect of complete response and type of therapy in multiple myeloma. (2013) (0)
- Impact of high-dose melphalan followed by autologous stem cell transplant in producing MRD negative complete response in newly diagnosed multiple myeloma. (2022) (0)
- Comment on Leleu et al , page 1968 , and Richardson et al , page 1961 “ IM iD ” eally treating multiple myeloma (2013) (0)
- Evaluation of pretransplant variables predicting cardiomyopathy following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. (2011) (0)
- A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis (2020) (0)
- Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome (2018) (0)
- Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis (2020) (0)
- The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma (2016) (0)
- Correction to: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis (Leukemia, (2020), 34, 4, (1135-1143), 10.1038/s41375-019-0655-x) (2020) (0)
- 1105-172 Abnormal vascular endothelial function in cardiac amyloidosis (2004) (0)
- Erratum: Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT (Bone Marrow Transplantation (2014) 49 (996) DOI:10.1038/bmt.2014.24) (2014) (0)
- Impact of Duration of Induction Therapy on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation (2017) (0)
- Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation (2022) (0)
- Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels. (2020) (0)
- The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia. (2004) (0)
- Amyloidosis Composite Response Score Incorporating the Depth of Organ Response (2021) (0)
- A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM) (2020) (0)
- Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma (2018) (0)
- Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma. (2007) (0)
- Allogeneic Stem Cell Transplantation (2014) (0)
- Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis (2019) (0)
- Gene Expression Profiling Identifies 4 Sub-Classes with Distinct Clinical Associations in Hyperdiploid Myeloma. (2005) (0)
- lymphoma hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin Early lymphocyte recovery predicts superior survival after autologous (2013) (0)
- Declining early mortality in stem cell transplantation for multiple myeloma (2000) (0)
- Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. (2022) (0)
- 88: Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceeding Plasma Cell Disorders (2008) (0)
- Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment (2022) (0)
- P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma (2022) (0)
- Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL). (2017) (0)
- Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma (2023) (0)
- Impact of Acquired Del(17p) in Patients with Multiple Myeloma (2018) (0)
- Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents. (2006) (0)
- A simple additive staging system for newly diagnosed multiple myeloma (2022) (0)
- Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia (2018) (0)
- Patient-Reported Outcome Driven Case Management System for Hematology — a Prospective Study (2018) (0)
- Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation (2010) (0)
- Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM). (2018) (0)
- IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia (2021) (0)
- Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100 (2022) (0)
- Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival. (2008) (0)
- Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma (2007) (0)
- AL amyloidosis: An overlooked cause of malabsorption syndrome (2000) (0)
- MM-431: A Comparison Between Daratumumab and Non-Daratumumab-Based Salvage Regimens Used at First Relapse Post-Lenalidomide Maintenance in Multiple Myeloma (2021) (0)
- Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT. (2007) (0)
- Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination (2022) (0)
- A584 Preliminary Results of a Phase I Trial of Intravenous MV-NIS for Relapsed/Refractory Multiple Myeloma (2009) (0)
- Absolute Values of Serum Immunoglobulin Free Light Chains Predict for Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant. (2005) (0)
- Serum Uric Acid Is a Novel Prognostic Factor in Patients with Primary Systemic Amyloidosis. (2007) (0)
- Is There Still a Role for High-Dose Melphalan and Stem Cell Transplantation in the Treatment of Multiple Myeloma? (2014) (0)
- Utilization of Cryopreserved Stem Cell Re-Infusion without Conditioning Chemotherapy in Primary and Secondary Autologous Graft Failure Following an Autologous Stem Cell Transplant in Multiple Myeloma (2020) (0)
- Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab (2022) (0)
- Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis (2016) (0)
- Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. (2021) (0)
- Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes (2022) (0)
- Autologous Stem Cell Transplantation Provides Additional Cytoreduction Following Induction Therapy in Multiple Myeloma. (2006) (0)
- Stem Cell Transplant in Multiple Myeloma: Impact of Response Failure in the Era of Novel Therapies. (2009) (0)
- Allogeneic Stem Cell Transplantation (ASCT) and Donor Lymphocyte Infusions (DLI) in the Management of Chronic Myelomonocytic Leukemia (CMML). (2005) (0)
- Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival (2022) (0)
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. (2012) (0)
- Recovery of polyclonal immunoglobulin serum levels to normal levels after autologous stem cell transplantation predicts disease free survival in patients with multiple myeloma. (2006) (0)
- Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia (2020) (0)
- The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation (2011) (0)
- Rare Concomitance of Primary Systemic Amyloidosis with Immunoglobulin M Monoclonal Gammopathy or Waldenstrom Macroglobulinemia. (2004) (0)
- Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy (2010) (0)
- Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis (2018) (0)
- A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents (2016) (0)
- Timing of Stem Cell Transplantation and Outcomes in Light Chain Amyloidosis (2016) (0)
- Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. (2009) (0)
- Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab (2021) (0)
- Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis (2022) (0)
- N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM) (2015) (0)
- Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM). (2021) (0)
- OAB-037: Assessing the prognostic utility of the Mayo 2018 and IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosis (2021) (0)
- The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis (2011) (0)
- The Transcriptome of Immunomodulator-Resistant Multiple Myeloma (2019) (0)
- Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome (2022) (0)
- Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL). (2005) (0)
- failure with thalidomide or lenalidomide induction Stem cell transplantation in multiple myeloma: impact of response (2012) (0)
- Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma. (2006) (0)
- Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation. (2010) (0)
- Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006 (2010) (0)
- AL amyloidosis patients prognostic factor of first-year survival after stem cell transplantation in Excessive fluid accumulation during stem cell mobilization: a novel (2013) (0)
- Comparative Proteomic Analysis of Skin in Acute Graft-Versus-Host Disease Compared to Autologous Graft-Versus-Host Disease and Normal Skin (2017) (0)
- Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes. (2005) (0)
- Autologous Stem Cell Transplant for IgM Related AL Amyloidosis (2019) (0)
- Survival trends in young patients with Waldenstrom macroglobulinemia (WM). (2015) (0)
- Transplantation without Growth Factor. Engraftment Kinetics Following Stem Cell Transplantation for Primary Systemic Amyloidosis. (2006) (0)
- Outcomes after relapse from first autologous stem cell transplantation in multiple myeloma. (2014) (0)
- Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma (2016) (0)
- Gene Expression Profiling of Hyperdiploid Multiple Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature. (2005) (0)
- Response to Rituximab in Type II Cryoglobulinemia. (2005) (0)
- Poster: MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM) (2021) (0)
- Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT). (2015) (0)
- Incidence of Cardiac Arrhythmias During Autologous Peripheral Blood Stem Cell Transplantation (2012) (0)
- Brief report Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma (2011) (0)
- CD34+ Cell Dose and Full Donor Chimerism at Day +100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphalan Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies (2009) (0)
- Measurement of the proliferation of clonal plasma cells by multiparametric flow cytometry is a clinically useful tool in relapsed multiple myeloma (2015) (0)
- 100: Fluid Related Complications with Filgrastim (G-CSF) 10 mcg/kg Once Daily Versus 5 mcg/kg Twice Daily in Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Mobilization (2008) (0)
- The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients (2015) (0)
- Combination T herapy W ith T halidomide P lus D examethasone for N ewly D iagnosed M yeloma (2002) (0)
- Abstract CT090: Rational design of an oncolytic virus permits use of interferon beta as a pharmacodynamic marker for clinical application (2019) (0)
- Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation. (2004) (0)
- Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma ORIGINAL ARTICLE (2010) (0)
- Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes (2021) (0)
- Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades (2021) (0)
- nonhyperdiploid dichotomy in MGUS A validated FISH trisomy index demonstrates the hyperdiploid and (2013) (0)
- To the editor: First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis (2016) (0)
- Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition (2019) (0)
- Synchronous pityriasis lichenoides et varioliformis acuta and lymphoplasmacytic lymphoma: a distinct association (2021) (0)
- Redefining Engraftment Syndrome: The New Mayo Clinic Criteria (2013) (0)
- Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response. (2020) (0)
- Prevention of active multiple myeloma (MM) using IL-1 receptor antagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP) (2007) (0)
- Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma (2016) (0)
- Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma (2019) (0)
- 138Lymphocyte recovery after allogeneic stem cell transplantation: Comparison of bone marrow and peripheral blood stem cell transplantation (2003) (0)
- Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment. (2010) (0)
- Outcome of Very Young (≤ 40 Years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study (2016) (0)
- Pilot study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with POEMS Syndrome (2019) (0)
- Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma. (2007) (0)
- Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy (2016) (0)
- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (2018) (0)
- PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA (2019) (0)
- Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine (2011) (0)
- Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy (2012) (0)
- The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome (2008) (0)
- Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL). (2017) (0)
- Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide (2022) (0)
- Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM). (2014) (0)
- Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis (2018) (0)
- amyloidosis Activity of pomalidomide in patients with immunoglobulin light-chain (2012) (0)
- P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients (2022) (0)
- Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma (2019) (0)
- Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma (2022) (0)
- An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS) (2021) (0)
- P-164: Daratumumab, carfilzomib, pomalidomide and elotuzumab for the treatment of poems syndrome: the Mayo Clinic experience (2022) (0)
- Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma (2018) (0)
- Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation (2016) (0)
- Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL). (2015) (0)
- The use of sequential living donor kidney and autologous stem cell transplantation for patients with primary (Al) amyloidosis and advanced renal failure (2004) (0)
- Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States (2022) (0)
- Use of autologous stem cells cryopreserved for over 15 years in stem cell transplantation for multiple myeloma (2020) (0)
- Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis (2016) (0)
- P-211: Changes in serum alkaline phosphatase levels during induction therapy to predict outcomes in patients with newly diagnosed multiple myeloma (2022) (0)
- Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma (2020) (0)
- Predicting Poor Peripheral Blood Stem Cell Mobilization Using Initial Peripheral CD34 Counts in Patients with Lymphoma. (2009) (0)
- P-129: Simultaneous versus consecutive assessment of disease markers for defining progressive disease in multiple myeloma (2022) (0)
- Natural history of multiple myeloma with de novo del(17p) (2019) (0)
- diagnosis and follow-up of patients with POEMS syndrome The utility of plasma vascular endothelial growth factor levels in the (2013) (0)
- Gene expression signatures of conventional prognostic factors in multiple myeloma (2005) (0)
- Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes (2022) (0)
- Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience (2021) (0)
- Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients (2021) (0)
- Updated Results of the Mayo Clinic Risk Adapted Algorithm for Peripheral Blood Stem Cell Mobilization Utilizing G-CSF and Plerixafor (2015) (0)
- Role of Second Stem Cell Transplant in Patients with Amyloidosis Who Are Refractory or Relapsing. (2005) (0)
- Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma (2013) (0)
- Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation (2022) (0)
- In reply [2] (2007) (0)
- A Hematopoietic Score Predicts Survival in Newly Diagnosed Multiple Myeloma Patients. (2019) (0)
- Continued monoclonal protein response beyond day 100 after auto-transplantation for multiple myeloma. (2013) (0)
- Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis (2020) (0)
- Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma (2020) (0)
- A Multidisciplinary Quality Initiative for Stem Cell Transplantation in Multiple Myeloma: Outpatient Transplant with Low Therapy Related Mortality (2008) (0)
- Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH (2018) (0)
- Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma (2020) (0)
- Salvage Autologous Stem Cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant Therapy (2018) (0)
- Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization. (2010) (0)
- AL Amyloidosis and Patient Reported Quality of Life (2015) (0)
- Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceeding Plasma Cell Disorders. (2007) (0)
- Long-Term Survivorship with Active Multiple Myeloma (2018) (0)
- Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma (2013) (0)
- A Phase II Study of Alemtuzumab in the Treatment of Plasma Cell Disorders. (2006) (0)
- Predictors of Early Treatment Failure following initial therapy for Systemic Immunoglobulin Light Chain Amyloidosis (2017) (0)
- 94: Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect? (2008) (0)
- Impact of Minimal Residual Negativity on Outcomes in Light Chain Amyloidosis (2019) (0)
- Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial (2015) (0)
- analysis of 411 patients dexamethasone in newly diagnosed multiple myeloma: a comparative Lenalidomide plus dexamethasone versus thalidomide plus (2013) (0)
- Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy (2014) (0)
- MM-429: Impact of Prolonged Lenalidomide Maintenance (≥3 years) and Outcomes in Patients with Multiple Myeloma Post-Autologous Stem Cell Transplant (2021) (0)
- MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM) (2021) (0)
- Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma (2019) (0)
- Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review (2020) (0)
- Natural history of delp53 multiple myeloma. (2018) (0)
- Autologous Stem Cell Transplantation In Immunoglobulin Light Chain Amyloidosis With Factor X Deficien (2013) (0)
- P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant (2022) (0)
- Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents (2016) (0)
- Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience (2018) (0)
- Prognostic Role of IL-6 in POEMS Syndrome (2021) (0)
- Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma (2019) (0)
- Oral Abstract: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia (2021) (0)
- 844-3 Preserved radial strain explains normal ejection fraction in cardiac amyloidosis patients with abnormal longitudinal strain (2004) (0)
- myeloma patients treated with high-dose therapy Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in (2013) (0)
- Blood mass spectrometry Detects Residual Disease Better than Standard Techniques in Immunoglobulin light chain amyloidosis (2019) (0)
- Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity? (2019) (0)
- P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP (2022) (0)
- Genomic Analysis of High Hyperdiploid Acute Lymphoblastic Leukemia and Hyperdiploid Multiple Myeloma Suggests Differential Gene Dosage Effect on Expression and Provide Clues to Preferential Selection of Recurrently Trisomic Chromosomes. (2005) (0)
- MARKERS ASSOCIATED WITH SHORT SURVIVAL IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: PF484 (2019) (0)
- Experience with Autologous HSC Transplant in Therapy-Related MDS/AML Using Cells Harvested Prior to the Development of the Secondary Malignancy. (2007) (0)
- 639P Conditional survival in MM and impact of prognostic factors over time (2022) (0)
- 59-year-old man with pelvic pain and hypergammaglobulinemia. (2001) (0)
- The Impact of Circulating Plasma Cells at Transplant on Survival in Multiple Myeloma in the Era of Novel Agents (2016) (0)
- Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients with Previous Diagnosis of Multiple Myeloma (MM). (2009) (0)
- Clinical outcomes in t(11;14) multiple myeloma. (2015) (0)
- Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis (2020) (0)
- Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event (2022) (0)
- Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. (2019) (0)
- Compendium of Karyotypic Abnormalities and Their Clinical Implications in Hyperdiploid Multiple Myeloma (H-MM). (2005) (0)
- Progression and Outcome in Patients with Biclonal Gammopathies (2014) (0)
- Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL) (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Martha Q Lacy?
Martha Q Lacy is affiliated with the following schools:
